[PDF][PDF] Juvenile myelomonocytic leukemia
C Kratz, C Niemeyer - Hematology, 2005 - Taylor & Francis
Juvenile myelomonocytic leukemia (JMML) is a rare clonal myeloproliferative disorder
(MPD) of early childhood [1]. The median age at diagnosis is 2 years [1]. There is a male …
(MPD) of early childhood [1]. The median age at diagnosis is 2 years [1]. There is a male …
[HTML][HTML] Трансплантация гемопоэтических стволовых клеток при ювенильном миеломоноцитарном лейкозе: анализ опыта одного центра и обзор литературы
МА Масчан, ЛА Хачатрян, ЮВ Скворцова… - …, 2011 - cyberleninka.ru
Аллогенная трансплантация гемопоэтических стволовых клеток (ТГСК) стандарт
терапии пациентов с ювенильным миеломоноцитарным лейкозом (ЮММЛ). В статье …
терапии пациентов с ювенильным миеломоноцитарным лейкозом (ЮММЛ). В статье …
Allogeneic stem cell transplantation in children with leukemia using human leukocyte antigen‐mismatched unrelated donors
P Sedlacek, R Formankova, E Mejstrikova… - Pediatric …, 2008 - Wiley Online Library
Allogeneic HSCT is a curative treatment, when chemotherapy fails, for certain malignant
diseases. In Europe, only 15% of the indicated children have an HLA‐matched sibling …
diseases. In Europe, only 15% of the indicated children have an HLA‐matched sibling …
[HTML][HTML] Cytosine arabinoside and mitoxantrone followed by second allogeneic transplant for the treatment of children with refractory juvenile myelomonocytic …
SA Patel, DW Coulter, AC Grovas… - Journal of pediatric …, 2014 - journals.lww.com
Hematopoietic stem cell transplantation (HSCT) remains the only curative option for most
patients with juvenile myelomonocytic leukemia (JMML). However, persistent disease and …
patients with juvenile myelomonocytic leukemia (JMML). However, persistent disease and …
Stem cell transplant as an immunomodulatory tool for children with hematologic malignancies
JL LaBelle, JM Cunningham - American Society of Clinical Oncology …, 2013 - ascopubs.org
Allogeneic stem cell transplantation (alloHSCT) is the most common and effective form of
immunotherapy used for treatment of pediatric leukemias. A combination of graft …
immunotherapy used for treatment of pediatric leukemias. A combination of graft …
Allo-SCT in children with high-risk leukemia using unmanipulated grafts from alternative donors
P Sedlacek, E Mejstrikova, R Formankova… - Bone Marrow …, 2008 - nature.com
Allogeneic HSCT is a curative treatment for high-risk leukemia. In Europe, approximately
15% of children have an HLA-matched sibling, but in 65–70% HLA allele-matched (9 …
15% of children have an HLA-matched sibling, but in 65–70% HLA allele-matched (9 …
[HTML][HTML] Donor KIR Gene Content and KIR-Ligand Matching and Outcomes of Pediatric Patients with JMML Following Unrelated Donor Transplant
HG Rangarajan, MSF Pereira… - … and cellular therapy, 2021 - ncbi.nlm.nih.gov
Background: Natural killer (NK) cell determinants predict relapse-free survival after
allogeneic hematopoietic cell transplant (HCT) for acute myeloid leukemia, and prior studies …
allogeneic hematopoietic cell transplant (HCT) for acute myeloid leukemia, and prior studies …
[HTML][HTML] Juvenile Myelomonocytic Leukemia Treatment (PDQ®)
PDQPTE Board - PDQ Cancer Information Summaries [Internet], 2024 - ncbi.nlm.nih.gov
This PDQ cancer information summary for health professionals provides comprehensive,
peer-reviewed, evidence-based information about the treatment of juvenile myelomonocytic …
peer-reviewed, evidence-based information about the treatment of juvenile myelomonocytic …